January 30, 2015
The results of a phase 1 clinical trial suggest a monovalent Ebola vaccine was safe and immunogenic in healthy adults, according to recently published data.
“Whether we have a vaccine that is safe, effective and works, we won’t know for a while yet,” Adrian V.S. Hill, DM, of the Jenner Institute at Oxford University, said in a press release. “We owe it to the people who have been affected so badly by the Ebola outbreak to find out.”